首页 > 最新文献

Blood Research最新文献

英文 中文
Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma. 伊鲁替尼联合吉西他滨-长春瑞滨治疗原发性难治性非霍奇金淋巴瘤。
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023182
Muruvvet Seda Aydin, Esra Cengiz, Ferda Can, Simten Dagdas, Imdat Dilek, Gulsum Ozet
{"title":"Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma.","authors":"Muruvvet Seda Aydin, Esra Cengiz, Ferda Can, Simten Dagdas, Imdat Dilek, Gulsum Ozet","doi":"10.5045/br.2023.2023182","DOIUrl":"10.5045/br.2023.2023182","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in cellular immunotherapy for lymphoid malignancies. 淋巴细胞恶性肿瘤细胞免疫治疗的最新进展。
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023177
Haerim Chung, Hyunsoo Cho

Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in our endogenous T-cells to kill tumor cells with a focus on the basic principles of T-cell receptor recognition of major histocompatibility complex-peptide complexes. We review the factors associated with CAR T-cell outcomes and recent efforts to employ CAR T-cells in earlier lines of therapy. We also discuss the value of bispecific T-cell engagers as off-the-shelf products with better toxicity profiles. Finally, natural killer cells are discussed as an important cellular immunotherapy platform with the potential to broaden immunotherapeutic applications beyond lymphoid malignancies.

嵌合抗原受体(CAR) t细胞的细胞免疫治疗已经彻底改变了淋巴细胞恶性肿瘤的治疗。本文综述了CAR在内源性t细胞中表达以杀死肿瘤细胞的必要性,重点介绍了t细胞受体识别主要组织相容性复合物-肽复合物的基本原理。在这里,我们回顾了与CAR - t细胞结果相关的因素以及最近在早期治疗中使用CAR - t细胞的努力。我们还讨论了双特异性t细胞结合物作为具有改进毒性特征的现成产品的价值。最后,自然杀伤细胞作为一种重要的细胞免疫治疗平台,具有扩大淋巴细胞恶性肿瘤免疫治疗应用的潜力。
{"title":"Recent advances in cellular immunotherapy for lymphoid malignancies.","authors":"Haerim Chung, Hyunsoo Cho","doi":"10.5045/br.2023.2023177","DOIUrl":"10.5045/br.2023.2023177","url":null,"abstract":"<p><p>Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in our endogenous T-cells to kill tumor cells with a focus on the basic principles of T-cell receptor recognition of major histocompatibility complex-peptide complexes. We review the factors associated with CAR T-cell outcomes and recent efforts to employ CAR T-cells in earlier lines of therapy. We also discuss the value of bispecific T-cell engagers as off-the-shelf products with better toxicity profiles. Finally, natural killer cells are discussed as an important cellular immunotherapy platform with the potential to broaden immunotherapeutic applications beyond lymphoid malignancies.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma. 新诊断弥漫性大b细胞淋巴瘤红细胞分布宽度/血小板计数与预后的关系
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023156
Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun

Background: Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the prognosis of diffuse large B-cell lymphoma (DLBCL). Therefore, this study aimed to investigate the correlation between RPR and the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma.

Methods: We retrospectively studied 143 patients with newly diagnosed DLBCL and used the median value as the RPR threshold. We also investigated the correlation of pretreatment RPR level with clinical characteristics and its impact on DLBCL prognosis.

Results: Using the median value as the cut-off, patients with DLBCL were divided into a low RPR group (<0.0549) and a high RPR group (≥0.0549). Patients in the high RPR group were older, had a later Ann Arbor stage, were prone to bone marrow invasion, and had a higher National Comprehensive Cancer Network International Prognostic Index score (P<0.05). A survival analysis showed that progression-free survival (PFS) (P=0.003) and overall survival (OS) (P<0.0001) were significantly shorter in the high versus low RPR group. A multifactorial Cox analysis showed that bone marrow invasion and elevated lactate dehydrogenase (LDH) were separate risk factors for PFS (P<0.05), while an RPR ≥0.0549 and elevated LDH were separate risk factors for OS (P<0.05).

Conclusion: A high RPR (≥0.0549) in patients with newly diagnosed DLBCL is an independent risk factor for a poor prognosis.

背景:红细胞分布宽度/血小板计数比(RPR)是许多疾病可靠的预后评估指标。然而,目前还没有研究证实RPR与弥漫性大b细胞淋巴瘤(DLBCL)预后之间的关系。因此,本研究旨在探讨RPR与弥漫性大b细胞淋巴瘤患者临床特征及预后的相关性。方法:对143例新诊断的DLBCL患者进行回顾性研究,采用中位数作为RPR阈值。我们还研究了预处理RPR水平与临床特征的相关性及其对DLBCL预后的影响。结果:以中位数为临界值,将DLBCL患者分为低RPR组(PP=0.003)和总生存期(OS)组(ppp)。结论:新诊断DLBCL患者高RPR(≥0.0549)是预后不良的独立危险因素。
{"title":"Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma.","authors":"Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun","doi":"10.5045/br.2023.2023156","DOIUrl":"10.5045/br.2023.2023156","url":null,"abstract":"<p><strong>Background: </strong>Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the prognosis of diffuse large B-cell lymphoma (DLBCL). Therefore, this study aimed to investigate the correlation between RPR and the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma.</p><p><strong>Methods: </strong>We retrospectively studied 143 patients with newly diagnosed DLBCL and used the median value as the RPR threshold. We also investigated the correlation of pretreatment RPR level with clinical characteristics and its impact on DLBCL prognosis.</p><p><strong>Results: </strong>Using the median value as the cut-off, patients with DLBCL were divided into a low RPR group (<0.0549) and a high RPR group (≥0.0549). Patients in the high RPR group were older, had a later Ann Arbor stage, were prone to bone marrow invasion, and had a higher National Comprehensive Cancer Network International Prognostic Index score (<i>P</i><0.05). A survival analysis showed that progression-free survival (PFS) (<i>P</i>=0.003) and overall survival (OS) (<i>P</i><0.0001) were significantly shorter in the high versus low RPR group. A multifactorial Cox analysis showed that bone marrow invasion and elevated lactate dehydrogenase (LDH) were separate risk factors for PFS (<i>P</i><0.05), while an RPR ≥0.0549 and elevated LDH were separate risk factors for OS (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>A high RPR (≥0.0549) in patients with newly diagnosed DLBCL is an independent risk factor for a poor prognosis.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study. 重型β-地中海贫血患者的促氧化剂/抗氧化剂平衡与血液参数的关系:一项横断面研究。
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023174
Maryam Parvizi, Maryam Deldadeh Moghaddam, Shiva Nazari, Hami Ashraf, Maryam Kazemi Aghdam

Background: Oxidative stress due to iron accumulation in patients with beta-thalassemia major (BTM) causes complications such as tissue damage and destruction. This study aimed to assess the association between the serum prooxidant/antioxidant balance (PAB) and blood parameters in patients with BTM.

Methods: This cross-sectional study included 92 patients with BTM. In this study, PAB was measured using an enzyme-linked immunosorbent assay (ELISA). Serum ferritin, blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), thyroid-stimulating hormone (TSH), total cholesterol (TC), triglyceride (TG), complete blood cell count (CBC), and history of blood transfusion were recorded. The association of the blood parameters was assessed across the tertiles (T) of serum PAB (highest T vs. lowest T).

Results: The results showed that high serum ferritin was directly associated with serum PAB [odds ratio (OR), 12.80; 95% confidence interval (CI), 2.98‒54.91; T3 vs. T1]. Also, direct associations were found for high TC (OR, 4.97; 95% CI, 1.42‒17.32; T3 vs. T1), high ALT (OR, 4.95; 95% CI, 1.33‒18.46; T3 vs. T1) and high TSH (OR, 3.78; 95% CI, 1.10‒13.02; T3 vs. T1).

Conclusion: The findings of the present study showed that serum PAB levels were directly associated with ferritin, ALT, TC, and TSH levels. This indicates that improvements in blood parameters, especially ferritin and TSH levels, occur by ameliorating oxidative stress in patients with BTM.

背景:重型地中海贫血(BTM)患者因铁蓄积而产生的氧化应激会导致组织损伤和破坏等并发症。本研究旨在评估 BTM 患者血清原氧化剂/抗氧化剂平衡(PAB)与血液参数之间的关联:这项横断面研究包括 92 名 BTM 患者。本研究采用酶联免疫吸附测定法(ELISA)测量原氧化剂/抗氧化剂平衡。研究还记录了血清铁蛋白、血尿素氮 (BUN)、肌酐 (Cr)、丙氨酸氨基转移酶 (ALT)、天冬氨酸氨基转移酶 (AST)、促甲状腺激素 (TSH)、总胆固醇 (TC)、甘油三酯 (TG)、全血细胞计数 (CBC) 和输血史。结果显示,高血清铁蛋白与低血清铁蛋白之间的关系非常密切:结果显示,高血清铁蛋白与血清 PAB 直接相关[几率比(OR),12.80;95% 置信区间(CI),2.98-54.91;T3 与 T1]。此外,高 TC(OR,4.97;95% CI,1.42-17.32;T3 vs. T1)、高 ALT(OR,4.95;95% CI,1.33-18.46;T3 vs. T1)和高 TSH(OR,3.78;95% CI,1.10-13.02;T3 vs. T1)也与 PAB 直接相关:本研究结果表明,血清 PAB 水平与铁蛋白、谷丙转氨酶、总胆固醇和促甲状腺激素水平直接相关。这表明,BTM 患者血液参数的改善,尤其是铁蛋白和促甲状腺激素水平的改善,是通过改善氧化应激而实现的。
{"title":"The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study.","authors":"Maryam Parvizi, Maryam Deldadeh Moghaddam, Shiva Nazari, Hami Ashraf, Maryam Kazemi Aghdam","doi":"10.5045/br.2023.2023174","DOIUrl":"10.5045/br.2023.2023174","url":null,"abstract":"<p><strong>Background: </strong>Oxidative stress due to iron accumulation in patients with beta-thalassemia major (BTM) causes complications such as tissue damage and destruction. This study aimed to assess the association between the serum prooxidant/antioxidant balance (PAB) and blood parameters in patients with BTM.</p><p><strong>Methods: </strong>This cross-sectional study included 92 patients with BTM. In this study, PAB was measured using an enzyme-linked immunosorbent assay (ELISA). Serum ferritin, blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), thyroid-stimulating hormone (TSH), total cholesterol (TC), triglyceride (TG), complete blood cell count (CBC), and history of blood transfusion were recorded. The association of the blood parameters was assessed across the tertiles (T) of serum PAB (highest T vs. lowest T).</p><p><strong>Results: </strong>The results showed that high serum ferritin was directly associated with serum PAB [odds ratio (OR), 12.80; 95% confidence interval (CI), 2.98‒54.91; T3 vs. T1]. Also, direct associations were found for high TC (OR, 4.97; 95% CI, 1.42‒17.32; T3 vs. T1), high ALT (OR, 4.95; 95% CI, 1.33‒18.46; T3 vs. T1) and high TSH (OR, 3.78; 95% CI, 1.10‒13.02; T3 vs. T1).</p><p><strong>Conclusion: </strong>The findings of the present study showed that serum PAB levels were directly associated with ferritin, ALT, TC, and TSH levels. This indicates that improvements in blood parameters, especially ferritin and TSH levels, occur by ameliorating oxidative stress in patients with BTM.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal aortic calcification in patients newly diagnosed with essential thrombocythemia. 新诊断为原发性血小板增多症患者的腹主动脉钙化。
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 Epub Date: 2023-10-19 DOI: 10.5045/br.2023.2023125
Myung-Won Lee, Jeong Suk Koh, Sora Kang, Hyewon Ryu, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Seon Young Kim, Seong Soo Kim, Deog-Yeon Jo

Background: Although atherosclerosis is likely to be involved in the development of arterial thrombotic events in patients with essential thrombocythemia (ET), abdominal aortic calcification (AAC) has rarely been investigated. We evaluated the prevalence and clinical relevance of AAC at the time of ET diagnosis.

Methods: This retrospective study included patients newly diagnosed with ET who underwent abdominal computed tomography (CT) at the time of diagnosis between January 2002 and December 2021 at Chungnam National University Hospital, Daejeon, Korea. CT images were reviewed and an aortic calcification score was assigned.

Results: Of the 94 patients (median age, 62 yr; range, 18‒90 yr), AAC was detected in 62 (66.0%). AAC was most commonly mild (33.0%), followed by moderate (22.7%) and severe (5.3%). Old age [odds ratio (OR), 34.37; 95% confidence interval (CI), 12.32‒95.91; P<0.001] was an independent risk factor for AAC. The patients with AAC had a higher WBC count (11.8±4.7 vs. 9.7±2.9×109/L, P=0.017), higher neutrophil-to-lymphocyte ratio (4.3±2.7 vs. 3.1±1.5, P=0.039), and higher JAK2V617F positivity (81.5% vs. 58.8%, P=0.020) compared to those without AAC. AAC was an independent risk factor for arterial thrombotic vascular events that occurred before or at diagnosis of ET (OR, 4.12; 95% CI, 1.11‒15.85; P=0.034).

Conclusion: AAC is common in patients with ET and is associated with arterial thrombotic events.

背景:尽管动脉粥样硬化可能与原发性血小板增多症(ET)患者动脉血栓事件的发生有关,但腹主动脉钙化(AAC)很少被研究。我们评估了在ET诊断时AAC的患病率和临床相关性。方法:本回顾性研究包括2002年1月至2021年12月在韩国大田忠南国立大学医院接受腹部计算机断层扫描(CT)诊断的新诊断为ET的患者。对CT图像进行复查,并对主动脉钙化进行评分。结果:在94例患者中(中位年龄62岁;范围18-90岁),AAC检出率为62例(66.0%)。AAC最常见的是轻度(33.0%),其次是中度(22.7%)和重度(5.3%)。老年[比值比(OR)=34.37,95%置信区间(CI)=12.32-95.91,P9/L,P=0.017),中性粒细胞与淋巴细胞的比值较高(4.3±2.7 vs.3.1±1.5,P=0.039),JAK2V617F阳性率较高(81.5%vs.58.8%,P=0.020)与没有AAC的那些相比。AAC是ET诊断前或诊断时发生动脉血栓性血管事件的独立危险因素(or=4.12,95%CI=1.11-15.85,P=0.034)。结论:AAC在ET患者中常见,与动脉血栓性事件有关。
{"title":"Abdominal aortic calcification in patients newly diagnosed with essential thrombocythemia.","authors":"Myung-Won Lee, Jeong Suk Koh, Sora Kang, Hyewon Ryu, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Seon Young Kim, Seong Soo Kim, Deog-Yeon Jo","doi":"10.5045/br.2023.2023125","DOIUrl":"10.5045/br.2023.2023125","url":null,"abstract":"<p><strong>Background: </strong>Although atherosclerosis is likely to be involved in the development of arterial thrombotic events in patients with essential thrombocythemia (ET), abdominal aortic calcification (AAC) has rarely been investigated. We evaluated the prevalence and clinical relevance of AAC at the time of ET diagnosis.</p><p><strong>Methods: </strong>This retrospective study included patients newly diagnosed with ET who underwent abdominal computed tomography (CT) at the time of diagnosis between January 2002 and December 2021 at Chungnam National University Hospital, Daejeon, Korea. CT images were reviewed and an aortic calcification score was assigned.</p><p><strong>Results: </strong>Of the 94 patients (median age, 62 yr; range, 18‒90 yr), AAC was detected in 62 (66.0%). AAC was most commonly mild (33.0%), followed by moderate (22.7%) and severe (5.3%). Old age [odds ratio (OR), 34.37; 95% confidence interval (CI), 12.32‒95.91; <i>P</i><0.001] was an independent risk factor for AAC. The patients with AAC had a higher WBC count (11.8±4.7 vs. 9.7±2.9×10<sup>9</sup>/L, <i>P</i>=0.017), higher neutrophil-to-lymphocyte ratio (4.3±2.7 vs. 3.1±1.5, <i>P</i>=0.039), and higher <i>JAK2</i>V617F positivity (81.5% vs. 58.8%, <i>P</i>=0.020) compared to those without AAC. AAC was an independent risk factor for arterial thrombotic vascular events that occurred before or at diagnosis of ET (OR, 4.12; 95% CI, 1.11‒15.85; <i>P</i>=0.034).</p><p><strong>Conclusion: </strong>AAC is common in patients with ET and is associated with arterial thrombotic events.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flower-shaped lymphocytes in CD5+ diffuse large B-cell lymphoma's leukemic phase. CD5+弥漫性大B细胞淋巴瘤白血病期的花形淋巴细胞。
IF 2.2 Q3 Medicine Pub Date : 2023-12-31 Epub Date: 2023-10-19 DOI: 10.5045/br.2023.2023178
Verónica Roldán Galiacho, Paula Zoco Gallardo, Laura Zaldumbide Dueñas, Bernabé Dávila De Las Fuentes, Juan Carlos García-Ruiz
{"title":"Flower-shaped lymphocytes in CD5+ diffuse large B-cell lymphoma's leukemic phase.","authors":"Verónica Roldán Galiacho, Paula Zoco Gallardo, Laura Zaldumbide Dueñas, Bernabé Dávila De Las Fuentes, Juan Carlos García-Ruiz","doi":"10.5045/br.2023.2023178","DOIUrl":"10.5045/br.2023.2023178","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A challenging diagnosis of hepatosplenic T cell lymphoma in a 10-year-old child. 一例10岁儿童肝脾T细胞淋巴瘤的挑战性诊断。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 DOI: 10.5045/br.2023.2023132
Sadiq Khalaf Ali, Saad Abdulbaqi Alomar, Hussam Mahmood Salih, Nooran Salem Yaseen
the potential to escalate to a maximum of 25 mg bid. However, in contrast to decitabine, greater caution is necessary when combined with intensive cytotoxic chemotherapy. Thus, further research is needed to determine the appropriate dosing. In summary, our case highlights that the combination of ruxolitinib and AML-style cytotoxic chemotherapy is an attractive option for older patients with post-MPN AML. Given the heterogeneity of this population and the lack of treatment options, further exploration of the role of ruxolitinib in combination with cytotoxic chemotherapy is required.
{"title":"A challenging diagnosis of hepatosplenic T cell lymphoma in a 10-year-old child.","authors":"Sadiq Khalaf Ali,&nbsp;Saad Abdulbaqi Alomar,&nbsp;Hussam Mahmood Salih,&nbsp;Nooran Salem Yaseen","doi":"10.5045/br.2023.2023132","DOIUrl":"https://doi.org/10.5045/br.2023.2023132","url":null,"abstract":"the potential to escalate to a maximum of 25 mg bid. However, in contrast to decitabine, greater caution is necessary when combined with intensive cytotoxic chemotherapy. Thus, further research is needed to determine the appropriate dosing. In summary, our case highlights that the combination of ruxolitinib and AML-style cytotoxic chemotherapy is an attractive option for older patients with post-MPN AML. Given the heterogeneity of this population and the lack of treatment options, further exploration of the role of ruxolitinib in combination with cytotoxic chemotherapy is required.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/67/br-58-3-157.PMC10548286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误表。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 DOI: 10.5045/br.2023.2023036e1
{"title":"Erratum.","authors":"","doi":"10.5045/br.2023.2023036e1","DOIUrl":"https://doi.org/10.5045/br.2023.2023036e1","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/ad/br-58-3-164.PMC10548283.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intrasinusoidal proerythroblast infiltration in therapy related myeloid neoplasm. 窦内原红细胞浸润在治疗相关髓系肿瘤中的应用。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-07-24 DOI: 10.5045/br.2023.2023112
Jian Li, Merit Hanna
A 67-year-old patient received rituximab and bendamustine for follicular lymphoma and achieved complete response two years prior to developing moderate anaemia (94 g/L) and thrombocytopenia (44×10 9 /L). Blood film showed circulating nucleated red cells and proerythroblasts with dysplasia (A, B). Diagnostic bone marrow aspirate was a dry tap. Trephine imprints showed 42% nucleated red cells with significant dysplasia such as binucleation, nuclear irregularity and cytoplasmic vacuoles (C). Immature erythroblasts were increased but comprised < 30% of nucleated cells. There was minimal maturation beyond the proerythroblast phase. Trephine core was hypercellular with abnormal megakaryocytes and erythroblasts (D). The latter showed weak membranous staining with anti-CD117 (E) and variable patterns of glycophorin A (F). Intra-sinusoidal infiltration of proerythroblasts were highlighted. There was no evidence for increased myeloblasts, granulocytic
{"title":"Intrasinusoidal proerythroblast infiltration in therapy related myeloid neoplasm.","authors":"Jian Li,&nbsp;Merit Hanna","doi":"10.5045/br.2023.2023112","DOIUrl":"10.5045/br.2023.2023112","url":null,"abstract":"A 67-year-old patient received rituximab and bendamustine for follicular lymphoma and achieved complete response two years prior to developing moderate anaemia (94 g/L) and thrombocytopenia (44×10 9 /L). Blood film showed circulating nucleated red cells and proerythroblasts with dysplasia (A, B). Diagnostic bone marrow aspirate was a dry tap. Trephine imprints showed 42% nucleated red cells with significant dysplasia such as binucleation, nuclear irregularity and cytoplasmic vacuoles (C). Immature erythroblasts were increased but comprised < 30% of nucleated cells. There was minimal maturation beyond the proerythroblast phase. Trephine core was hypercellular with abnormal megakaryocytes and erythroblasts (D). The latter showed weak membranous staining with anti-CD117 (E) and variable patterns of glycophorin A (F). Intra-sinusoidal infiltration of proerythroblasts were highlighted. There was no evidence for increased myeloblasts, granulocytic","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/ec/br-58-3-126.PMC10548291.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report. RUNX1-RUNX1T1和BCR-ABL1在急性髓系白血病中共存1例报告。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-08-25 DOI: 10.5045/br.2023.2023120
Suji Park, Jae-Ryong Shim, Ji Hyun Lee, Jin-Yeong Han
REFERENCES 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90. 2. Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF. Hairy cell leukaemia: a heterogeneous disease? Br J Haematol 2008;142:45-51. 3. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15. 4. Cortazar JM, DeAngelo DJ, Pinkus GS, Morgan EA. Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology 2017;71:112-24. 5. Hammond WA, Swaika A, Menke D, Tun HW. Hairy cell lymphoma: a potentially under-recognized entity. Rare Tumors 2017;9:6518. 6. Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine 2008;9:374-6. 7. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502. 8. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): longterm follow-up of the Northwestern University experience. Blood 2005;106:241-6. 9. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26. Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report
{"title":"Co-existence of <i>RUNX1-RUNX1T1</i> and <i>BCR-ABL1</i> in acute myeloid leukemia: a case report.","authors":"Suji Park,&nbsp;Jae-Ryong Shim,&nbsp;Ji Hyun Lee,&nbsp;Jin-Yeong Han","doi":"10.5045/br.2023.2023120","DOIUrl":"10.5045/br.2023.2023120","url":null,"abstract":"REFERENCES 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90. 2. Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF. Hairy cell leukaemia: a heterogeneous disease? Br J Haematol 2008;142:45-51. 3. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15. 4. Cortazar JM, DeAngelo DJ, Pinkus GS, Morgan EA. Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology 2017;71:112-24. 5. Hammond WA, Swaika A, Menke D, Tun HW. Hairy cell lymphoma: a potentially under-recognized entity. Rare Tumors 2017;9:6518. 6. Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine 2008;9:374-6. 7. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502. 8. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): longterm follow-up of the Northwestern University experience. Blood 2005;106:241-6. 9. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26. Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/25/br-58-3-151.PMC10548288.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1